Nature1mon
Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer
We generated a new type of MHC multimers, which can be monomerized in the presence of a competitor, resulting in rapid loss of the staining reagent. Following dissociation, the T cells are ...
Baylor College of Medicine4y
MHC Tetramer Suggested Staining Protocol
Add 25ml to each well of a microtiter plate or test tube. Prepare 2x staining cocktail containing all of your labeled reagents at the right titer. The suggested titer for the MHC tetramer reagent is 1 ...
BioWorld1mon
Quanta Therapeutics reports new KRAS mutant inhibitors for cancer
Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.
Business Insider1mon
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
“With the initiation of the Phase 1 clinical trial for QTX3544 in patients with KRAS G12V-driven solid tumors, we will have three KRAS inhibitor programs in the clinic focused on the most ...
Pharmabiz1mon
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
QTX3544 is a multi-KRAS inhibitor with G12V-preferring activity. The Phase 1 clinical trial will initially enroll patients with KRASG12V mutations in dose escalation cohorts as monotherapy and in ...